ArticleClinical science (London, England : 1979)2015
Interleukin 34: a new modulator of human and experimental inflammatory bowel disease.
Article in Clinical science (London, England : 1979), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 106 citations in OpenAlex.
- The plasticity and metabolic reprogramming of macrophage in ulcerative colitis.Frontiers in immunology · 2026Review
- Quinic and Ferulic Acid-Loaded Chitosan Nanoparticles Attenuate Experimental Ulcerative Colitis by Modulating the IL-32/IL-33/IL-34 Axis and NF-κB Signaling.International journal of inflammation · 2026Article
- Mutation in the rat interleukin 34 gene impacts macrophage development, homeostasis, and inflammation.Life science alliance · 2025Article
- Macrophages: Subtypes, Distribution, Polarization, Immunomodulatory Functions, and Therapeutics.MedComm · 2025Review
- Elevated levels of salivary interleukin-34 in patients suffering from Alzheimer's disease.Clinical oral investigations · 2025Article
- Role of IL-34 in Tumors and Its Application to Regulate Inflammation.Cancer science · 2025Review
- Layer-specific molecular signatures of colon anastomotic healing and leakage in mice.Molecular medicine (Cambridge, Mass.) · 2025Article
- Intestinal epithelium-derived IL-34 reprograms macrophages to mitigate gastrointestinal tract graft-versus-host disease.Science translational medicine · 2025Article
- Anti-Inflammatory Effects of Algae-Derived Biomolecules in Gut Health: A Review.International journal of molecular sciences · 2025Review
- IL-34 aggravates myocardial ischemia-reperfusion injury by upregulating the HMGB1-IL-17A-IL-6 axis through the JAK signaling pathway.PloS one · 2025Article
- M-CSF Protects Against Ulcerative Colitis via Aconitate: Mendelian Randomization and Experimental Evidence.Journal of inflammation research · 2025Article
- The distinct role of IL-34 and IL-35 in gastric cancer.Frontiers in immunology · 2025Review
- Prognostic role of IL-34 in sepsis and sepsis-induced acute lung injury: preliminary results and future directions.Acta biochimica Polonica · 2025Article
- Inflammation accelerating intestinal fibrosis: from mechanism to clinic.European journal of medical research · 2024Review
- The relationship between extreme inter-individual variation in macrophage gene expression and genetic susceptibility to inflammatory bowel disease.Human genetics · 2024Article
- Cut-off value for interleukin-34 as an additional potential inflammatory biomarker for estimation of slow coronary flow risk.BMC cardiovascular disorders · 2024Observational
- Huang Lian Jie Du decoction attenuated colitis via suppressing the macrophage Csf1r/Src pathway and modulating gut microbiota.Frontiers in immunology · 2024Article
- Selected Cytokines and Metalloproteinases in Inflammatory Bowel Disease.International journal of molecular sciences · 2023Review
- Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.Clinical and experimental medicine · 2023Article
- Cellular and Molecular Mechanisms of Intestinal Fibrosis.Gut and liver · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IBD (inflammatory bowel disease), where CD (Crohn's disease) and UC (ulcerative colitis) represent the two main forms, are chronic inflammatory conditions of the intestine. Macrophages play a central role in IBD pathogenesis and are regulated by major differentiation factors such as CSF-1 (colony-stimulating factor 1) in homoeostasis and inflammation. IL (interleukin)-34 has recently been discovered as a second ligand for CSF-1R (CSF-1 receptor). However, expression and involvement of IL-34 in IBD remain unknown. In the present paper, we investigated the expression of IL34, CSF1 and their shared receptor CSF1R in normal human ileum and colon, in inflamed and non-inflamed tissues of CD and UC patients, and in a mouse model of experimental colitis. We found distinct expression patterns of IL34 and CSF1 in ileum and colon, with higher IL34 in ileum and, in contrast, higher CSF1 in colon. Furthermore, IL34 and CSF1 expression was increased with inflammation in IBD patients and in experimental colitis. In humans, infiltrating cells of the lamina propria and intestinal epithelial cells expressed IL-34, and TNF-α (tumour necrosis factor α) regulated IL-34 expression in intestinal epithelial cells through the NF-κB (nuclear factor κB) pathway. These data demonstrate the expression pattern of IL-34 in ileum and colon and suggest IL-34 as a new modulator of inflammation in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.